These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38436677)

  • 1. Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials.
    Zid Y; Robertson NP
    J Neurol; 2024 Apr; 271(4):2141-2143. PubMed ID: 38436677
    [No Abstract]   [Full Text] [Related]  

  • 2. Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report.
    Puig-Casadevall M; Álvarez-Bravo G; Varela AQ; Robles-Cedeño R; Sànchez Cirera L; Miguela A; Laguillo G; Montalban X; Hauser SL; Ramió-Torrentà L
    Eur J Neurol; 2023 Oct; 30(10):3357-3361. PubMed ID: 37485841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
    Mancinelli CR; Scarpazza C; Cordioli C; De Rossi N; Rasia S; Turrini MV; Capra R
    Mult Scler; 2021 Apr; 27(5):790-794. PubMed ID: 32749910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab.
    Toorop AA; van Lierop ZYG; Strijbis EEM; Teunissen CE; Petzold A; Wattjes MP; Barkhof F; de Jong BA; van Kempen ZLE; Killestein J
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33051344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE).
    Smoot K; Marginean H; Gervasi-Follmar T; Chen C; Repovic P; Cohan S
    Mult Scler; 2023 Jul; 29(8):956-966. PubMed ID: 37317841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen.
    Hervás JV; Presas-Rodríguez S; Crespo-Cuevas AM; Canento T; Lozano-Sánchez M; Massuet-Vilamajó A; Ramo-Tello C
    Neurodegener Dis Manag; 2015 Oct; 5(5):399-402. PubMed ID: 26517599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-interval dosing of natalizumab in NOVA.
    Stüve O; Tugemann B
    Lancet Neurol; 2023 Mar; 22(3):199-200. PubMed ID: 36804084
    [No Abstract]   [Full Text] [Related]  

  • 8. Extended-interval dosing of natalizumab in NOVA - Authors' reply.
    Foley JF; Campbell N; Kong G
    Lancet Neurol; 2023 Mar; 22(3):200-201. PubMed ID: 36804085
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deaths and disability from natalizumab are no longer tolerable: Commentary.
    Hutchinson M
    Mult Scler; 2012 Aug; 18(8):1073. PubMed ID: 22807472
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
    Foley JF; Defer G; Ryerson LZ; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Smirnakis K; Xiao S; Kong G; Kuhelj R; Campbell N;
    Lancet Neurol; 2022 Jul; 21(7):608-619. PubMed ID: 35483387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
    Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.
    Warnke C; Hartung HP
    Mult Scler; 2017 Jun; 23(7):920-922. PubMed ID: 28481191
    [No Abstract]   [Full Text] [Related]  

  • 14. Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk.
    Marignier R; Durand-Dubief F; du Pasquier R; Vukusic S
    Ann Neurol; 2016 Nov; 80(5):791. PubMed ID: 27554031
    [No Abstract]   [Full Text] [Related]  

  • 15. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Ziemssen T; Gass A; Wuerfel J; Bayas A; Tackenberg B; Limmroth V; Linker R; Mäurer M; Haas J; Stangel M; Meergans M; Harlin O; Hartung HP
    BMC Neurol; 2016 Jul; 16():98. PubMed ID: 27405225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reply to "Serum Neurofilaments as Candidate Biomarkers of Natalizumab Progressive Multifocal Leukoencephalopathy".
    Dalla Costa G; Martinelli V; Furlan R; Comi G
    Ann Neurol; 2019 Aug; 86(2):324. PubMed ID: 31187511
    [No Abstract]   [Full Text] [Related]  

  • 17. Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy.
    Loonstra FC; Verberk IMW; Wijburg MT; Wattjes MP; Teunissen CE; van Oosten BW; Uitdehaag BMJ; Killestein J; van Kempen ZLE
    Ann Neurol; 2019 Aug; 86(2):322-324. PubMed ID: 31192473
    [No Abstract]   [Full Text] [Related]  

  • 18. Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
    Bigaut K; Kremer L; Fabacher T; Ahle G; Goudot M; Fleury M; Gaultier C; Courtois S; Collongues N; de Seze J
    J Neurol; 2022 Jun; 269(6):3295-3300. PubMed ID: 34982200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis.
    Moccia M; Loperto I; Santoni L; Masera S; Affinito G; Carotenuto A; Lanzillo R; Triassi M; Morra VB; Palladino R
    Neurodegener Dis Manag; 2022 Jun; 12(3):109-116. PubMed ID: 35446149
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of natalizumab in persons with multiple sclerosis: 2022 update.
    Morrow SA; Clift F; Devonshire V; Lapointe E; Schneider R; Stefanelli M; Vosoughi R
    Mult Scler Relat Disord; 2022 Sep; 65():103995. PubMed ID: 35810718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.